Skip to content

Voyager Life PLC - Result of GM and Additional Subscription


Announcement provided by

Voyager Life plc · VOY

21/03/2023 07:00

Voyager Life PLC - Result of GM and Additional Subscription
RNS Number : 5945T
Voyager Life PLC
21 March 2023
 

 

21 March 2023

 

Voyager Life plc

 

("Voyager" or the "Company") 

 

Result of General Meeting, Additional Subscription and Issue of Equity

 

 

The General Meeting of the Shareholders of Voyager was held yesterday at 11.00 am (UK) at Tay House, Riverview Business Park, Friarton Road, Perth, Perthshire PH2 8DF. The Company is pleased to confirm that all resolutions were duly passed and announces a further subscription of new ordinary shares in the Company by an existing shareholder for £20,000.

 

Full details of the poll results are set out below:

 

Resolution

For

Against

Discretion to Chairman

Percentage of Voting Rights

Withheld

Total

01

558,631

Nil

Nil

4.60%

2,161,776

2,720,407

02

2,720,407

Nil

Nil

22.38%

Nil

2,720,407

03

2,720,407

Nil

Nil

22.38%

Nil

2,720,407

 

The number of ordinary shares in issue at 6:30 p.m. (UK) on 17 March 2023 was 12,152,912. The Company does not hold any shares in treasury.

 

Additional Subscription and Issue of Equity

 

Following approval of Rule 9 Waiver granted under the Takeover Code, Eric Boyle, chairman, and Nick Tulloch, CEO, have each subscribed for 833,333 new ordinary shares of 1 pence each ("New Ordinary Shares") at a price of 12 pence per New Ordinary Share with a warrant to subscribe for an additional New Ordinary Share at an exercise price of 20 pence.  These are the same terms as the fundraise announced at the time of the Company's acquisition of the CBD extraction and manufacturing facility in Poland from Goodbody Health Limited on 16 December 2022.

 

In addition, an existing shareholder has also subscribed for 166,666 New Ordinary Shares at a price of 12 pence per New Ordinary Share with a warrant to subscribe for an additional New Ordinary Share at an exercise price of 20 pence raising further funds of £20,000 for Voyager.

 

Admission

 

Application has been made for 1,833,332 new ordinary shares to be admitted to trading on the Aquis Stock Exchange Growth Market ("Admission"). Admission is expected to occur at 8:00 am on or around 24 March 2023. The new ordinary shares will rank pari passu with the existing ordinary shares.

 

Total Voting Rights

 

Following Admission, the Company's enlarged share capital will comprise 13,986,244 ordinary shares ordinary shares of 1 pence each. Therefore, the total number of voting rights in the Company will be 13,986,244. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

ENDS

 

Enquiries:

Voyager Life plc

 

Nick Tulloch, CEO

 

 

 

Tel: +44 (0) 1738 317 693

 

http://voyagerlife.uk

nick@voyagerlife.uk

 

Cairn Financial Advisers LLP (AQSE Corporate Adviser)

 

Ludovico Lazzaretti/Liam Murray

 

Tel: +44 (0) 20 7213 0880

Stanford Capital Partners LLP (Broker)

 

Patrick Claridge  

 

Bob Pountney

 

John Howes

 

 

 

+44 (0) 203 3650 3650

 

+44 (0) 203 3650 3651

 

+44 (0) 203 3650 3652

 

Notes to Editors:

 

About Voyager

Voyager was founded in 2020 and is based in Perth, Scotland.  The Company's primary objective is the formulation and supply of high quality CBD and hemp seed oil products although it also produces several other complementary products, the majority of which are manufactured from the hemp plant.  Its product categories include a pet range which has rapidly developed into one of the Company's best sellers.   The Company sells online, through third party stores and in its own stores which are located in St Andrews, Edinburgh and Dundee.  The Company has two principal retail brands: Voyager, focused on health & wellness, and Ascend Skincare, its beauty range.  Voyager products are currently available from Cornwall to Shetland in over 150 online and brick-and-mortar outlets. In December 2022, with the aim of expanding its manufacturing capability for EU markets, Voyager purchased a state-of-the-art CBD extraction and manufacturing facility in Poland.

 

The Company's philosophy of plant-based health and wellness is embodied in its mission statement and hashtag of "Choose you". With an experienced team and a product line created in line with the UK's regulatory regime, Voyager aims to become the trusted brand in this increasingly popular health and wellness space.

 

Through Voyager's bespoke skincare product creation and development division, voyagerCann, the Company also offers a full turnkey service to other CBD, skincare and cosmetics brands assisting them in developing and launching new products with manufacturing and distribution facilities in Scotland and Poland.

 

Website and social media links:

Voyager:

https://voyagercbd.com/

https://www.instagram.com/voyagercbd/

https://twitter.com/voyagercbd

https://www.linkedin.com/company/voyager-cbd/

https://www.facebook.com/voyagercbd/

 

voyagerCann:

https://voyagercann.com/

https://www.instagram.com/voyagercann/

https://twitter.com/voyagercann/

https://www.linkedin.com/company/voyagercann/

https://www.facebook.com/voyagercann/

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Nicholas Tulloch

2.

Reason for the notification

a)

Position / status

CEO

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, UK emission allowance market participant, auction platform or auctioneer

a)

Name

Voyager Life plc

b)

LEI

213800XIUQ3AHRZ6UF89

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Subscription of new ordinary shares of 1 pence each and issue of warrants over new ordinary shares of 1 pence each

b)

Nature of the transaction

Investment in the Company following approval of the Rule 9 Waiver granted by the Takeover Panel

c)

Price(s) and volume(s)

Price(s)

Volume(s)

12 pence

833,333



20 pence (warrants)

833,333








d)

Aggregated information Aggregated volume Price

N/A

 

e)

Date of the transaction

20 March 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Eric Boyle

2.

Reason for the notification

a)

Position / status

Chairman

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, UK emission allowance market participant, auction platform or auctioneer

a)

Name

Voyager Life plc

b)

LEI

213800XIUQ3AHRZ6UF89

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Subscription of new ordinary shares of 1 pence each and issue of warrants over new ordinary shares of 1 pence each

b)

Nature of the transaction

Investment in the Company following approval of the Rule 9 Waiver granted by the Takeover Panel

c)

Price(s) and volume(s)

Price(s)

Volume(s)

12 pence

833,333



20 pence (warrants)

833,333








d)

Aggregated information Aggregated volume Price

N/A

 

e)

Date of the transaction

20 March 2023

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXGZGZFMGKGFZZ ]]>

View more ...

VOY announcementsAll announcements

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal